Succharated ferric oxide
8047-67-4O.O.O.OC[C@H]1O[C@@](CO)(O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@@H]1O.[Fe+3].[Fe+3].[Fe+3].[Fe+3].[Fe+3].[Na+].[Na+].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[OH-]ADQSUDSYBZBMFT-JMMWHMDLNA-HIron sucrose (sucroferric oxyhydroxide or iron saccharate) is used as a source of iron in patients with iron deficiency anemia with chronic kidney disease (CKD), including those who are undergoing dialysis (hemodialysis or peritoneal) and those who do not require dialysis. Due to less side effects than iron dextran, iron sucrose is more preferred in chronic kidney disease patients.
8047-67-4Breast Feeding; Lactation; Milk, Human; Ferric Compounds; Hematinics; Iron Compounds
Breast Feeding; Lactation; Milk, Human; Ferric Compounds; Iron Compounds
EMA approved medicines: Human medicine
化学的特性Brown solid
安全情報は参考情報です。供給元の安全データシート(SDS)、適用法令、専門家による評価に代わるものではありません。
◉ Summary of Use during Lactation
◉ Summary of Use during Lactation
V - Various
QV - Various
Following intravenous administration, iron sucrose is dissociated into iron and sucrose and the iron is transported as a complex with transferrin to target cells including erythroid precursor cells. The iron is then incorporated into hemoglobin as the cells mature into red blood cells.
SUCROFERRIC OXYHYDROXIDE
Phosphate Binder [EPC]; Phosphate Chelating Activity [MoA]
The intravensously administered iron sucrose injection would result rapidly in high serum iron levels. Maximum measured levels occured after 10 min of injection with an average of 30.00 mg/l.
Renal elimination of iron contributed very little to the total elimination (in average less than 5%). While, renal elimination of sucrose accounts for 68-75% of the administered dose after 4 and 24 hours respectively.
Vd is 7.3 L
Total body clearance is 20.5 ml/min.
現在のフィルター条件では反応記録がありません。
読み込み中…
使用Iron Saccharate has been used to treat iron deficiency and iron deficiency anemia associated with different chronic diseases.